STAT

Opinion: Canada is long overdue for a national registry of drug company payments to doctors

It is past time for Canada to create a national registry of payments that pharmaceutical and medical device companies make to health care providers.

Ontario recently took a historic step as the first province in Canada to introduce legislation that would shine a light on interactions between drug companies and prescribers. The use of the term “historic” here is not hyperbole, since the extent of payments by the pharmaceutical industry to individual physicians in Canada has never been known.

Other countries, such as the United States and France, have been making such information public for a few years now. But Ontario’s bill would provide a wider scope of transparency by including

You're reading a preview, sign up to read more.

More from STAT

STAT3 min read
Opinion: CBO Estimate On Pelosi Drug Bill Misses Its Long-term Impact On Health
The CBO estimate on Speaker Nancy Pelosi's drug pricing bill misses its long-term impact on health.
STAT5 min readScience
Opinion: Using CRISPR To Edit Eggs, Sperm, Or Embryos Does Not Save Lives
The real value of using CRISPR on eggs, sperm, or embryos accrues not to the individual who is created but to the people who choose to use it to create…
STAT4 min readSociety
An ‘Unprecedented’ Analysis Underlines Profound Failure To Study African Genomes
It has become the geneticist’s version of, “What, me not inclusive? But I have a black friend!” In the case of modern studies of DNA, researchers called to task for studying mainly European populations often defend themselves by pointing out that the